Wells Fargo & Company Anavex Life Sciences Corp. Transaction History

Wells Fargo & Company

$434 Billion
Q3 2024

A detailed history of Wells Fargo & Company transactions in Anavex Life Sciences Corp. stock. As of the latest transaction made, Wells Fargo & Company holds 130,794 shares of AVXL stock, worth $1.18 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

130,794

Previous 84,363 55.04%

Holding current value

$1.18 Million

Previous $356,000 108.43%

% of portfolio

0.0%

Previous 0.0%

19 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	BUY	$4.11 - $7.04 $190,831 - $326,874	46,431 Added 55.04%	130,794 $742,000
Q2 2024 Aug 13, 2024	BUY	$3.39 - $5.02 $38,771 - $57,413	11,437 Added 15.68%	84,363 $356,000
Q1 2024 May 10, 2024	BUY	$4.55 - $6.75 $21,749 - $32,265	4,780 Added 7.01%	72,926 $371,000
Q4 2023 Feb 09, 2024	SELL	$5.04 - $9.95 $219,416 - $433,173	-43,535 Reduced 38.98%	68,146 $634,000
Q3 2023 Nov 13, 2023	SELL	$6.55 - $9.37 $294,808 - $421,734	-45,009 Reduced 28.72%	111,681 $731,000
Q2 2023 Aug 15, 2023	SELL	$7.66 - $9.5 $22,122 - $27,436	-2,888 Reduced 1.81%	156,690 $1.27 Million
Q1 2023 May 12, 2023	BUY	$8.32 - $11.75 $577,532 - $815,626	69,415 Added 76.99%	159,578 $1.37 Million
Q4 2022 Feb 13, 2023	BUY	$7.65 - $14.43 $407,033 - $767,777	53,207 Added 143.97%	90,163 $834,000
Q3 2022 Nov 14, 2022	SELL	$8.9 - $12.86 $391 - $565	-44 Reduced 0.12%	36,956 $382,000
Q2 2022 Aug 12, 2022	SELL	$7.31 - $12.84 $519,368 - $912,269	-71,049 Reduced 65.76%	37,000 $370,000
Q1 2022 May 16, 2022	SELL	$9.74 - $17.69 $190,962 - $346,830	-19,606 Reduced 15.36%	108,049 $1.33 Million
Q4 2021 Feb 14, 2022	BUY	$16.88 - $23.31 $504,965 - $697,318	29,915 Added 30.61%	127,655 $2.21 Million
Q3 2021 Nov 15, 2021	BUY	$16.82 - $25.75 $115,031 - $176,104	6,839 Added 7.52%	97,740 $1.76 Million
Q2 2021 Aug 16, 2021	BUY	$10.16 - $28.86 $341,548 - $970,186	33,617 Added 58.68%	90,901 $2.08 Million
Q1 2021 May 13, 2021	SELL	$5.17 - $16.13 $458,625 - $1.43 Million	-88,709 Reduced 60.76%	57,284 $856,000
Q4 2020 Feb 09, 2021	SELL	$4.01 - $7.58 $21,666 - $40,954	-5,403 Reduced 3.57%	145,993 $788,000
Q3 2020 Nov 05, 2020	SELL	$3.8 - $5.0 $27,550 - $36,250	-7,250 Reduced 4.57%	151,396 $689,000
Q2 2020 Aug 13, 2020	BUY	$2.62 - $5.2 $92,276 - $183,144	35,220 Added 28.54%	158,646 $780,000
Q1 2020 May 14, 2020	BUY	$2.38 - $5.81 $293,753 - $717,105	123,426 New	123,426 $389,000

Others Institutions Holding AVXL

# of Institutions

155

Shares Held

27.3M

Call Options Held

515K

Put Options Held

838K

View Full List

About ANAVEX LIFE SCIENCES CORP.

Ticker AVXL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 77,942,800
Market Cap $705M
Description
Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the treatment of Alzheimer's disease; Phase III clinical trial to treat pediatric patien...

More about AVXL

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

News

Stay updated on Wells Fargo & Company with notifications on news.

Account

Wells Fargo & Company Anavex Life Sciences Corp. Transaction History